NCT03260491 | Phase I | 57 | Paritrutumab-deruxtecan | Locally advanced or metastatic EGFR mutant, pretreated (TKI) | 39% | 8.3 | 184 |
NCT03260491 expansion cohort | Phase I | 47 | Paritrutumab-deruxtecan | Locally advanced or metastatic without EGFR mutation, pretreated (platinum-based chemotherapy ± immunotherapy) | 28% | 5.4 | 142 |
NCT04676477 | Phase I | Enrolling | Paritrutumab-deruxtecan + osimertinib | Locally advanced or metastatic EGFR mutant, pretreated (osimertinib) | n.n. | n.n. | 185 |
eNRGy1 | Global multicenter registry | 20 | Afatinib | NSCLC with NRG1 rearrangements | 25% | 2.8 | 154 |
15 | Chemotherapy | NSCLC with NRG1 rearrangements | 13%–14% | 4.0-5.8 |
9 | Chemoimmunmotherapy | NSCLC with NRG1 rearrangements | 0% | 3.3 |
5 | Immunotherapy | NSCLC with NRG1 rearrangements | 20% | 3.6 |
eNRGy trial (NCT02912949) | Phase II | 46 | Zenocutuzumab (MCLA-128) | NRG1 fusion-positive NSCLC (pretreated) | 35% | n.n. | 186 |